GH

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.

Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026.

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.

Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses.

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47%.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor.